Drug Profile
Research programme: aldosterone synthase inhibitors - Schering-Plough
Alternative Names: MOERAS 115Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Organon
- Developer Schering-Plough
- Class
- Mechanism of Action Aldosterone synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Heart-failure in Netherlands
- 18 Jun 2008 Preclinical trials in Heart failure in Netherlands (unspecified route)
- 19 Nov 2007 Organon has been acquired and merged into Schering-Plough